-
Hidden Risks in Biopharma: Clinical and Economic Evidence
Read more →: Hidden Risks in Biopharma: Clinical and Economic EvidenceIn the complex world of biopharma, success hinges on more than just clinical breakthroughs. While regulatory approval is often celebrated as a significant milestone, it does not guarantee market access or patient adoption. A critical, yet frequently overlooked factor, is the integration of clinical and economic evidence during drug development and commercialization. The interplay between these…
-
Hidden Risks in Biopharma: Why Market Access and HTA Preparedness Matter
Read more →: Hidden Risks in Biopharma: Why Market Access and HTA Preparedness MatterIn the high-stakes world of biotechnology, success often seems to hinge on a single, defining goal: securing regulatory approval. For many biopharma leaders, finally receiving that green light from agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is a cause for celebration—and rightfully so. It represents years…
-
Loon Lens™: Autonomous AI Agents for Literature Screening in Systematic Reviews
Read more →: Loon Lens™: Autonomous AI Agents for Literature Screening in Systematic ReviewsWe are pleased to share the results of our recent validation study, “Loon Lens 1.0 Validation: Agentic AI for Title and Abstract Screening in Systematic Literature Reviews,” now available on medRxiv. This study evaluates the effectiveness of Loon Lens™, our autonomous AI literature screener designed to automate the Title and Abstract (TiAb) screening process in…